BR100 Increased By (0.52%)
BR30 Increased By (0.49%)
KSE100 Increased By (0.46%)
KSE30 Increased By (0.58%)
BECO 5.67 Decreased By ▼ -0.06 (-1.05%)
BML 57.03 Decreased By ▼ -0.27 (-0.47%)
BOP 36.90 Increased By ▲ 0.13 (0.35%)
CNERGY 8.32 Decreased By ▼ -0.07 (-0.83%)
DCL 11.93 Decreased By ▼ -0.11 (-0.91%)
FCCL 58.70 Increased By ▲ 0.09 (0.15%)
FCSC 5.10 Increased By ▲ 0.09 (1.8%)
FFL 18.08 Increased By ▲ 0.14 (0.78%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.31 Decreased By ▼ -0.11 (-0.96%)
KEL 8.26 Decreased By ▼ -0.03 (-0.36%)
KOSM 6.57 Decreased By ▼ -0.05 (-0.76%)
MLCF 107.69 Decreased By ▼ -0.60 (-0.55%)
NBP 209.48 Increased By ▲ 3.44 (1.67%)
PACE 11.20 Increased By ▲ 0.03 (0.27%)
PAEL 45.54 Increased By ▲ 0.19 (0.42%)
PIAHCLA 30.33 Decreased By ▼ -0.44 (-1.43%)
PIBTL 18.87 Decreased By ▼ -0.19 (-1%)
PPL 248.61 Increased By ▲ 2.66 (1.08%)
PRL 36.30 Increased By ▲ 0.22 (0.61%)
PTC 73.75 Increased By ▲ 1.39 (1.92%)
SEARL 96.28 Decreased By ▼ -0.39 (-0.4%)
SSGC 31.43 Decreased By ▼ -0.24 (-0.76%)
TELE 9.23 Decreased By ▼ -0.04 (-0.43%)
THCCL 68.20 Increased By ▲ 0.39 (0.58%)
TPLP 11.60 Increased By ▲ 0.37 (3.29%)
TREET 25.78 Decreased By ▼ -0.11 (-0.42%)
TRG 67.40 Decreased By ▼ -0.44 (-0.65%)
WAVES 11.24 Increased By ▲ 0.26 (2.37%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
By

ISLAMABAD: Federal Minister for Planning and Development Asad Umar said on Saturday that Pakistan was all set to participate in the Phase-III trials of a Chinese-developed coronavirus vaccine.

Taking to Twitter, the head of the National Command and Operations Centre (NCOC), Asad Umar, said, "Pakistan will be participating in phase 3 trials of a Chinese developed vaccine for coronavirus. The trials in Pakistan will Insha Allah start in about 10 days' time."

It is pertinent to mention here that Pakistan's first Phase-III clinical trial for CanSino's candidate, Ad5-nCoV, will be led by the government-run National Institute of Health (NIH) along with a pharmaceutical company, AJM, the local representative of CanSino.

An NIH spokesman said that the Pakistan Health Research Council (PHRC) had also approved the clinical study, to be carried out in Karachi, Lahore and Islamabad.

The daily positive cases in Pakistan peaked at more than 6,000 in June but have since fallen sharply.

Comments

Comments are closed for this article.